Lyra therapeutics announces inducement grant under nasdaq listing rule 5635(c)(4)

Watertown, mass. , june 17, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, today announced that it has issued an equity-based award pursuant to its 2022 inducement award plan to its executive chairman, harlan w.
LYRA Ratings Summary
LYRA Quant Ranking